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Abstract 
Objective
The amount and distribution of fat and lean mass have important implications for health and systemic inﬂammation may 
represent a risk for altered body composition. The aim of this study was to analyse whether changes in body composition 
are similarly associated with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), two inﬂammatory 
conditions of different pathogenesis. 
Methods
Body mass index (BMI), waist circumference, fat mass (FM) and fat-free mass (FFM) were measured in 92 women with 
SLE, 89 with RA and 107 controls. Results were compared among the 3 groups and correlations of FM percentage were 
explored within SLE and RA.
Results
Abnormal body composition was more frequent in women with SLE and RA than in non-inﬂammatory controls, despite 
having a similar BMI. RA diagnosis was signiﬁcantly associated with overfat (OR=2.782, 95%CI 1.470–5.264; p=0.002) 
and central obesity (OR=2.998, 95%CI 1.016–8.841; p=0.04), while sarcopenia was more common among SLE 
(OR=3.003; 95%CI 1.178–7.676; p=0.01). Sarcopenic obesity, i.e. the coexistence of overfat with sarcopenia, was present 
in 6.5% of SLE and 5.6% of RA women, but no controls. Independent correlations of FM percentage in women with SLE 
included smoking, disease activity and CRP. In RA, education, disease activity and cumulative corticosteroid dose were 
identiﬁed as independent predictors of FM percentage.
Conclusion
Women with SLE or RA diagnosis are more likely to have abnormal body composition phenotype, with some differences 
existing between these two conditions. Changes in body composition are partly explained by the inﬂammatory burden of 
disease and its treatment.
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Introduction 
The amount and distribution of body 
fat and lean mass have important im-
plications for health. A very low body 
mass index (BMI) as well as obes-
ity are associated with reduced life 
expectancy, increased morbidity and 
poor quality of life (1-4).  Not only the 
amount of fat, but also the distribution 
of adipose tissue may have detrimental 
consequences on health. In fact, a dis-
proportionate accumulation of adipose 
tissue in the abdominal region, which 
is a key feature of metabolic syndrome, 
is associated with a prothrombotic and 
proinﬂammatory state and confers a 
higher risk of developing cardiovascu-
lar (CV) diseases (5, 6). Additionally, 
by secreting adipokines, adipose tissue 
actively participates in the inﬂamma-
tory process and higher concentrations 
of inﬂammatory markers are present in 
overweight and obese people, as well 
as in association with metabolic syn-
drome (3, 7).
Systemic lupus erythematosus (SLE) 
and rheumatoid arthritis (RA) are mul-
tisystemic rheumatic diseases that af-
fect joints and muscles, causing pain, 
disability and increased risk for physi-
cal inactivity (8). Patients often require 
prolonged therapy with corticosteroids 
which contributes to weight gain (9). 
Also, the systemic inﬂammatory nature 
of these diseases may, per se, represent 
an additional risk for altered body com-
position. In fact, in RA both cachexia 
and excessive fat mass have been iden-
tiﬁed more frequently than in the gener-
al population (10, 11). In the same way, 
abnormal body composition phenotypes 
may also be overrepresented among pa-
tients with SLE (12, 13), although infor-
mation regarding this patient group is 
limited. Moreover, metabolic syndrome 
was found more commonly in SLE and 
RA than in controls matched for age 
and sex (14, 15). Changes in body com-
position may therefore represent an ad-
ditional risk for cardiovascular diseases 
in SLE and RA.
The present work was undertaken to 
examine whether changes in body 
composition are similarly associated 
with SLE and RA, two chronic inﬂam-
matory conditions of different patho-
genesis, and to what extent the disease 
characteristics and pharmacotherapy 
affect the percentage of body fat mass. 
Material and methods
Study population
Adult Caucasian women, fulﬁlling 
the American College of Rheumatol-
ogy (ACR) criteria for SLE or for RA 
and attending the rheumatology clinic 
at Hospital Garcia de Orta in Almada, 
Portugal, on a regular basis, were eli-
gible for the study. The control group 
consisted of women without chronic 
inﬂammatory disorders (patients with 
tendinitis or with low back pain) attend-
ing the same clinic. Exclusion criteria 
were pregnancy, breastfeeding, ethnic-
ity other than Caucasian, functional 
class IV as deﬁned by the ACR clas-
siﬁcation of functional status, ischemic 
heart disease, and impaired renal func-
tion (serum creatinine >1.6 mg/dl). The 
study was approved by the local Ethics 
Committee and participants provided 
written informed consent. 
Between January and December 2009 
a total of 305 women were recruited. 
Five declined participation and 12 
were excluded. The reasons for exclu-
sion were heart disease in 9 cases and 
renal insufﬁciency in 3. The ﬁnal study 
population comprised 288 women: 92 
with SLE, 89 with RA and 107 con-
trols. Demographic and disease charac-
teristics are summarised in Table I.  
Participants underwent a structured 
interview and physical examination 
performed by the same trained investi-
gators. 
Anthropometric and body 
composition measurements
All assessments were carried out dur-
ing the morning of the study visit day 
with participants in the fasting state in 
order to minimise circadian variations. 
Standing height (in cm), and body 
weight (in kg) were measured with pa-
tients wearing light clothes and with-
out shoes, and body mass index (BMI) 
(kg/m2) was calculated. Waist circum-
ference was measured at the end of the 
normal expiration with a tape placed 
horizontally midway between the lower 
edge of the rib cage and the iliac crest, 
and the mean of two measurements 
was taken in account. Total fat mass 
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(in kg), percentage of body fat, and fat-
free mass (in kg) were obtained by bio-
electrical impedance analysis (BIA), 
using an Omron HBF-510 Full Body 
Composition analyser. BIA is a sim-
ple method for routine clinical use that 
correlates well with hydrodensitometry 
body fat analysis and with the “gold-
standard” dual-energy x-ray absorpti-
ometry (DXA) measurement (11). Fat 
mass index (FMI) was calculated by 
dividing  body fat mass by the square 
of the height (kg/m2) and fat-free mass 
index (FFMI) by dividing fat-free mass 
by the square of the height (kg/m2).
Clinical assessment
Socio-demographic data (age, meno-
pausal status, education), health habits 
(smoking status, physical activity), dis-
ease duration, current and past medica-
tions and co-morbidities were assessed 
by patient self-report and information 
was completed by review of medical 
records.
SLE disease activity was evaluated us-
ing the SLEDAI2K (16), a measure of 
ongoing disease activity that ranges 
from 0 to 105. Damage was scored ac-
cording to the Systemic Lupus Inter-
national Collaborating Clinics/ACR 
Damage Index (SDI) (17) from 0 to 46. 
In RA patients 28 joints were examined 
for tenderness and swelling, and the dis-
ease activity score (DAS28) was calcu-
lated using ESR. Disease activity was 
classiﬁed as low (DAS28 <3.2), medi-
um (DAS28 3.2–5.1) or high (DAS28 
>5.1) (18). Functional status (disabil-
ity) was evaluated using the Stanford 
Health Assessment Questionnaire Dis-
ability Index (HAQ) (19), a self-admin-
istered questionnaire that gives a score 
range from 0 to 3, with higher scores 
indicating lower functional capacity. 
SDI and HAQ were used as surrogate 
markers of cumulative disease sever-
ity. Blood and urine samples were col-
lected and the required tests performed 
in order to calculate SLE and RA dis-
ease activity (complete blood count, 
erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), creatine ki-
nase, anti-DNA antibody titer, C3 and 
C4 level and urinalysis).
Deﬁnitions
Participants were classiﬁed as physi-
cally active if the amount of self-re-
ported weekly aerobic exercise during 
the last 12 months was ≥3 times and 
≥30 min per session. Individuals with 
BMI <18.5 kg/m2 were considered un-
derweight, between 18.5 and 24.9 nor-
mal, between 25 and 29.9 overweight 
and with BMI values ≥30 obese. Ab-
dominal obesity was deﬁned in agree-
ment with WHO (20) and IDF (21) 
population recommended cut-points, 
which corresponds to a waist circum-
ference ≥80 cm in Caucasian women. 
Overfat was deﬁned according to total 
body FM percentage assessed by BIA. 
Women were considered overfat if their 
percentage of body fat was superior to 
40.01% (22). The cutoff to deﬁne sar-
copenia was a FFMI ≤2 SD below the 
mean of a reference Caucasian popula-
tion (23). On the basis of FM percent-
age and FFMI participants were cat-
egorised into purely obese (overfat), 
purely sarcopenic, sarcopenic-obese 
and normal body composition. 
Statistical analysis
Anthropometric and body composition 
parameters of SLE, RA and control 
women were compared using one-way 
analysis of variance for normally dis-
tributed continuous variables, with post 
hoc Bonferroni correction. To compare 
categorical variables Pearson χ2 test or 
Fisher’s exact test were used. 
The independent association between 
the inﬂammatory diseases and body 
composition phenotype was assessed 
by multiple logistic regression. The 
dependent variable “body composi-
tion” was dichotomised into normal 
body composition phenotype or altered 
body composition (purely obese, pure-
ly sarcopenic and sarcopenic obese) 
and the diagnosis, as well as potential 
confounders (age, BMI, current and cu-
mulative corticosteroid dose), were the 
covariates.
Subsequently, the impact of clinical 
features and treatment on fat mass per-
centage was investigated separately 
among patients with SLE and those 
with RA by using linear logistic regres-
sion. Variables related in univariate 
analyses to FM percentage at a p-value 
<0.20 were considered possible predic-
tors and included in the logistic model. 
Before performing regression analysis 
FM percentage was logarithmically 
transformed to obtain normality, as 
well as disease activity, SDI, corti-
costeroid dose, and CRP to ensure the 
normality of the residuals in multiple 
linear regression. Statistical calcula-
tions were performed using SPSS 17.0 
Table I. Demographic and clinical characteristics of studied women.
 SLE (n=92)    RA (n=89) Controls (n=107)
Demographics and lifestyle   
   Age, years 46.8 ± 14.1 49.8 ± 13.8 47.5 ± 13.1
   Menopause (%) 46 (50 %) 51 (57.3 %) 58 (54.2%)
   Education, years 9.3 ± 5.1 8.8 ± 4.8 8.4 ± 5.3
   Current smoker (%) 13 (14.1%) 16 (16.9%) 23 (21.5%)
   Physically active (%) 18 (19.6 %) 10 (11.2%) 20 (18.7%)
Disease characteristics   
   Disease duration, years 8.5 ± 6.9 9.7 ± 7.1 NA
   SLEDAI 2K 2 [4]     –  NA
   DAS28 –  4.24 ± 1.3 NA
   SDI 0 [1] –  NA
   HAQ –  1.16 ±  0.73 NA
Corticosteroids   
   Current use (%) 52 (56.5%) 46 (51.7%) NA
   Current daily dose, mg 5 [8.8] 2.5 [5] NA
   Cumulative dose, g 7.3 [20.7] 7.3 [15] NA
Data is presented as mean ± standard deviation for normally distributed, median and interquartile 
range [IQR] for non-normally distributed continuous variables and proportions (%) for categorical 
variables. 
SLEDAI2K: Systemic lupus erythematosus disease activity index 2000; DAS28: Disease activity 
score; SDI: Systemic lupus international collaborating clinics/ACR damage index; HAQ: Health as-
sessment questionnaire.
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software and a 2-tailed p-value <0.05 
was selected as signiﬁcant.
Results
Patients’ characteristics 
Patients and controls had similar so-
cio-demographic and lifestyle charac-
teristics, including age (p=0.31) and 
percentage of post-menopausal women 
(p=0.61). SLE and RA women did not 
differ signiﬁcantly with regard to dis-
ease duration or current corticosteroid 
use. Overall, 52 (56.5%) women with 
SLE and 46 (51.7%) with RA were 
on steroids at the time of evaluation. 
Among those taking steroids, the me-
dian daily dose was higher in SLE, but 
the cumulative corticosteroid dose was 
comparable in the 2 groups. The pro-
portion of lupus women on antimalar-
ials and on immunossupressants was 
73% and 33.6%, respectively. Eighty 
two RA women were treated with syn-
thetic disease-modifying anti-rheumat-
ic drugs (DMARDs), of which 92.7% 
were on methotrexate (MTX); 39.3% 
received biologics. The majority of 
SLE patients (80.4%) had low disease 
activity (SLEDAI<6) with a median 
SLEDAI value of 2 [IQR 0 to 4]; 25.3% 
of RA patients had low, 44.2% moder-
ate and 30.5% high disease activity and 
the mean DAS28 score was 4.24±1.3. 
Some irreversible damage was present 
in 40.2% of SLE patients and the me-
dian SDI value was 0 [IQR 0 to 1]. The 
mean HAQ score of RA patients was 
1.16 ±0.73. 
Anthropometric and body 
composition measurements
Table II shows anthropometric and 
body composition measurements. Pa-
tients and controls had comparable 
mean BMI. Patients with BMI<25 
kg/m2 were younger (p<0.001), pre 
menopause (p=0.006), current smokers 
(p=0.04), had higher education level 
(p<0.0001) and more active disease 
(p=0.03), compared with those with 
BMI≥25 kg/m2. No differences were 
found regarding physical active per-
sons, disease duration, disease severity, 
and corticosteroid use or dose.
Body fat mass (FM) was signiﬁcantly 
higher in women with RA than in non-
inﬂammatory controls across all BMI 
categories. Within the normal BMI 
range, SLE women also presented 
higher amount of FM. RA diagno-
sis was associated with greater odds 
of overfat (OR=2.782, 95%CI 1.470 
to 5.264, p=0.002). Low FM was ex-
ceptional; only 2 individuals in each 
inﬂammatory group and no controls 
had less than 20% of body fat. The 
mean value of FFM was similar across 
the 3 groups. However, signiﬁcantly 
more SLE patients were sarcopenic 
(OR=3.003; 95%CI 1.178 to 7.676; 
p=0.01). Moreover, 6.5% of SLE pa-
tients, 5.6% of RA patients but no con-
trols could be classiﬁed as sarcopenic 
obese (p=0.03). 
Compared with the control group, both 
SLE and RA women were less likely 
to have normal body composition. The 
adjusted OR for altered body composi-
tion was 2.581 (95% CI 1.234–5.396, 
Table II. Anthropometric and body composition characteristics of women with SLE, RA 
and control subjects.
 
 SLE (n=92) RA (n=89) Controls (n=107) p-value
BMI, kg/m2 27.0 ± 4.9 27.6 ± 5.0 26.7 ± 4.7 NS
FM, kg 24.2 ± 8.6 26.5 ± 8.8* 22.5 ± 7.8 0.006
FFM, kg 42.8 ± 7.0 42.6 ± 6.0 42.8 ± 6.6 NS
FM (kg) per BMI category:               
    Nomal 17.1 ± 4.2* 18.0 ± 5.5* 14.5 ± 4.3 0.04
    Overweight 24.7 ± 3.8 25.9 ± 4.0* 23.6 ± 3.3 0.05
    Obese 34.2 ± 6.6 35.6 ± 6.7* 31.9 ± 4.5 0.04
Body composition:
    Purely overfat 19 (20.7%) 31 (34.8%)* 20 (18.7%) 0.005
    Purely sarcopenic 10 (10.9%)* 4 (4.5%) 7 (6.5%) 0.04
    Sarcopenic obese 6 (6.5%)* 5 (5.6%)* 0 (0%) 0.03
    Healthy composition 56 (60.9%)* 49 (55.1%)* 80 (74.8%) 0.01
Central obesity, % 65 (70.7%) 79 (77.5%)* 67 (62.6%) 0.04
Variables are presented as mean ± SD or proportions (%).The three groups were compared using one-
way analysis of variance, χ2 or Fisher’s exact test with post-hoc Bonferroni correction for multiple 
comparisons. BMI: body mass index; FM: fat mass; FFM: free-fat mass.
*Signiﬁcant differences between groups are as follows: FM - RA vs. controls p=0.004; Fat mass within 
normal BMI range - SLE vs. controls p=0.04, RA vs. controls p=0.03; Fat mass within overweight 
BMI range - RA vs. controls p=0.04; Fat mass within BMI obese range - RA vs. controls p=0.02; Body 
composition: Purely overfat - RA vs. controls p=0.001; Purely sarcopenic - SLE vs. controls p=0.01; 
Sarcopenic obese - SLE vs. controls p=0.009; RA vs. controls p=0.01; Healthy body composition - 
SLE vs. controls p=0.04; RA vs. controls p=0.004; Central obesity - RA vs. controls p=0.02
Table III. Predictors of FM percentage in women with SLE.
 Univariate regression analysis Multiple regression analysis†
Explanatory variables β coefﬁcient*  p-value β coefﬁcient* p-value
Education, years -0.022 (-0.031 to -0.012) <0.0001 -0.003 (-0.013 to 0.007) 0.58
Smoking, Y/N -0.221 (-.355 to -0.089) 0.001 -0.13 (-0.243 to -0.016) 0.02
Physically active, Y/N -0.086 (-0.207 to 0.036) 0.16 -0.004 (-0.112 to 0.104) 0.93
Disease duration, years 0.058 (-0.004 to 0.119) 0.07 0.032 (-0.028 to 0.092) 0.29
Log (SLEDAI2K) -0.053 (-0.106 to 0.000) 0.05     -0.049 (-0.096 to -0.003) 0.03
Log (SDI)                                       0.218  (0.006 to 0.175)  0.03 -0.018 (-0.103 to 0.068) 0.69
Immunosuppressant use, Y/N 0.020 (-0.084 to 0.124) 0.70 – –
Log (Current  0.005 (-0.036 to 0.045) 0.82 – – 
        corticosteroid dose) 
Log (Cumulative  0.002 (-0.013 to 0.017) 0.79 – – 
        corticosteroid dose) 
Log (CRP)                                      0.100 (0.01 to 0.185)  0.02 0.088  (0.017 to 0.16)  0.01
FM: Fat mass; SLEDAI2K: Systemic lupus erythematosus disease activity index 2000; SDI: Systemic 
lupus international collaborating clinics /ACR damage index; CRP: C-reactive protein.
*Unstandardised coefﬁcients; †Multiple linear regression analysis was adjusted for age. The total 
explained variance of the model is R2=0.448.
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p=0.01) in SLE and 2.592 (95% 
CI1.246–5.392, p=0.01) in RA. 
The prevalence of central obesity dif-
fered signiﬁcantly from controls only 
in RA women. After adjustment for co-
variates, the risk of central obesity was 
almost 3 times higher in RA (OR=2.998, 
95%CI 1.016–8.841; p=0.04).
The relationships between clinical fea-
tures and percentage of FM in SLE 
women are presented in Table III. In 
univariate analysis there was a signiﬁ-
cant association of FM percentage with 
education, smoking, disease activity, 
damage and CRP. When possible pre-
dictors were entered in multiple linear 
regression analysis, smoking, disease 
activity and CRP were identiﬁed as in-
dependent predictors of FM percentage 
in lupus women. 
Table IV shows the relationships be-
tween clinical features and percentage 
of fat mass in RA women. A strong as-
sociation of education, HAQ and cu-
mulative corticosteroid dose with FM 
was observed. However, when clini-
cally important and possible predictors 
were adjusted for, education, disease 
activity and cumulative corticosteroid 
dose were identiﬁed as independent 
predictors of FM percentage in RA.
Discussion
In this cross-sectional study of women 
with SLE and RA we explored the re-
lationship between these two inﬂam-
matory rheumatic diseases and body 
composition. As fat mass, lean mass 
and fat distribution differ among differ-
ent ethnic groups (24), only Caucasians 
were included.   
The main ﬁnding is that Caucasian 
women with inﬂammatory rheumatic 
diseases are more likely to have abnor-
mal body composition phenotype than 
non-inﬂammatory controls, with some 
differences existing between SLE and 
RA. The amount of body fat is higher 
in RA women than in controls, regard-
less of having comparable mean BMI 
and a similar proportion of overweight 
and obesity according to the BMI cut-
offs. BMI does not discriminate be-
tween lean and fat mass, and the cutoff 
points of BMI for RA patients have 
been recently challenged (25). In RA, 
not only the amount of FM, but also the 
distribution of adipose tissue is altered. 
Indeed, the prevalence of central obes-
ity is signiﬁcantly higher in women 
with RA as compared to the control 
group. These ﬁndings may have im-
portant clinical implications as adipose 
tissue is a major source of adipokines 
involved in several metabolic and in-
ﬂammatory processes. Moreover, ab-
dominal obesity is a surrogate marker 
of visceral fat accumulation (26) and a 
well documented predictor of cardio-
vascular events (27). Abdominal obes-
ity is linked to the insulin resistance 
observed frequently in RA patients (14, 
28) and, while the effective control of 
inﬂammatory activity improves insulin 
resistance (29), serum levels of adipok-
ines seem to remain largely independ-
ent of short-term RA disease activity 
control (30, 31).
The mean fat-free mass was similar in 
our patients with inﬂammatory diseases 
and non-inﬂammatory controls. How-
ever, a signiﬁcantly greater proportion 
of SLE (17.4%) and RA (10.1%) wom-
en could be classiﬁed as sarcopenic, as 
compared with non-inﬂammatory con-
trols (6.5%). The excessive waste of 
fat-free mass found in SLE and RA has 
been attributed to disease activity and 
decreased physical activity. Addition-
ally, the catabolic effect of high corti-
costeroid doses (32), such as those used 
in severe lupus, might have contributed 
to the more frequently sarcopenia ob-
served in SLE patients. Reduced lean 
mass in combination with increased fat 
mass, a condition that is known as obese 
sarcopenia, was previously reported in 
older RA patients (10). Yet, we found 
obese sarcopenia as frequent in SLE 
(6.5%) as in RA (5.6%) women and 
absent among controls. In the general 
population, obese-sarcopenia is found 
in older people and is associated with 
worse physical function (33). Contro-
versy exist wheater cardiovascular risk 
is increased in rheumatic patients with 
sarcopenia (34). 
There is a close relationship between 
body fat and demographic and lifestyle 
characteristics. Nevertheless, disease 
activity and pharmacotherapy also af-
fect the percentage of body fat. The 
percentage of FM is lower in patients 
with higher disease activity, which may 
be explained by the catabolic effect of 
pro-inﬂammatory cytokines, in particu-
lar IL-6 and TNF, inducing weight and 
appetite loss (35, 36). In fact, despite 
not having measured cytokine levels, it 
has been shown that TNF levels are in-
creased in SLE and in RA as compared 
with controls (37, 38) and there is evi-
dence that an hypermetabolic state is as-
sociated with high levels of TNF, IL-1, 
and very active disease (39, 40). How-
ever, similarly to other authors (41), we 
could not depict an independent effect 
of TNF inhibition on total fat mass per-
centage in moderately active RA. 
Table IV. Predictors of FM percentage in women with RA.
 Univariate regression analysis Multiple regression analysis†
Explanatory variables β coefﬁcient* p-value β coefﬁcient* p-value
Education, years -0.023 (-0.032 to -0.014) <0.0001 -0.011 (-0.021 to 0.000) 0.04
Smoking, Y/N -0.126 (-0.236 to 0.010) 0.06 0.004 (-0.127 to 0.118) 0.94
Physically active, Y/N -0.029 (-0.193 to 0.136) 0.73 – –
Disease duration, years 0.07 (-0.002 to 0.143) 0.06 -0.004 (-0.010 to 0.003) 0.27
DAS28  -0.022 (-0.062 to 0.018) 0.13 -0.038 (-0.076 to -0.001) 0.04
HAQ  0.089 (0.015 to 0.158) 0.01 0.019 (-0.051 to 0.089) 0.59
DMARD use, Y/N -0.151 (-0.342 to 0.040) 0.12 -0.047 (-0.206 to 0.112) 0.55
TNF inhibitors, Y/N 0.096 (-0.007 to  0.198) 0.07 0.018 (-0.076 to 0.111) 0.70
Log (Current  0.037 (-0.017 to 0.09) 0.17 -0.005 (-0.053 to 0.055) 0.95 
        corticosteroid dose) 
Log (Cumulative  0.047 (0.020 to 0.075) 0.001 0.043 (0.014 to 0.073) 0.005 
        corticosteroid dose) 
Log (CRP) -0.05 (-0.155 to 0.055) 0.34 – –
FM: Fat mass; DAS28: Disease activity score; HAQ: Health assessment questionnaire; DMARD: 
Disease-modifying anti-rheumatic drug; TNF: tumour necrosis factor
*Unstandardised coefﬁcients. †Multiple linear regression analysis was adjusted for age. The total 
explained variance of the model is R2=0.542.
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The relationship of CRP and FM per-
centage is inverse in lupus patients and 
independent of SLEDAI. As CRP is not 
usually increased in active SLE, and 
no signiﬁcant correlation could be de-
tected between CRP and SLEDAI (data 
not shown), this ﬁnding may possible 
reﬂect higher CRP levels related to the 
adipose tissue itself. Current corticos-
teroid dose was not identiﬁed as an in-
dependent predictor of FM percentage. 
Corticosteroids are used in more active 
disease and, by controlling inﬂamma-
tion, low doses may counterbalance the 
catabolic effect of pro-inﬂammatory 
cytokines. 
Surprisingly, the observations on the 
amount of fat mass not associated with 
disease duration, disease severity, exer-
cise, DMARD or immunosuppressant 
use, a ﬁnding that deserves further re-
search. A possible explanation relates 
to the limitations of the cross sectional 
study design that cannot accurately as-
sess the cumulative effect of disease, 
medication and exercise over time. An-
other limitation of the present study is 
the lack of dietary intake evaluation, a 
known risk factor for altered body com-
position in the general population (42).
We cannot rule out differences in nutri-
ent intake related to medication or dis-
ease activity as decreased appetite and 
reduced protein intake may occur in 
highly active disease (41), but is usually 
normal when disease activity is control-
led (39). Additionally, 59.2% of patients 
were on steroids and even the small 
mean prednisolone dose could increase 
appetite. Nevertheless, our study popu-
lation comprised a wide spectrum of dis-
ease activity which might minimise the 
effect of inﬂammatory activity on appe-
tite, thus making signiﬁcant differences 
in food or nutrient intake between wom-
en with inﬂammatory disease and con-
trols from the same social and cultural 
background less likely. Another relevant 
variable in this context is physical activ-
ity. Physical activity did not emerge as 
having a relevant impact on FM. How-
ever, 81.5% of patients were sedentary, 
which means that the physically active 
group may have been too small to allow 
detection of a signiﬁcant effect. 
The rationale for a comparative study 
of two inﬂammatory rheumatic diseas-
es was based on the assumption that dif-
ferent inﬂammatory settings could have 
a diverse effect on the study param-
eters. Both diseases are associated with 
altered body composition phenotype, 
yet some differences could be detected 
between SLE and RA. While in RA 
an increase in FM and central obesity 
prevails, more SLE women presented 
decreased lean mass. Nevertheless, the 
independent negative effect of disease 
activity on body fat mass was simi-
larly observed in both diseases. These 
ﬁndings provide further support to the 
hypothesis that the alterations in body 
composition observed in inﬂammatory 
rheumatic diseases are partly explained 
by the inﬂammatory process itself. 
In conclusion, women with SLE and 
RA exhibit changes in body composi-
tion more frequently than non-inﬂam-
matory controls, which may, at least in 
part, be a consequence of the inﬂamma-
tory burden of the disease and its treat-
ment.  BIA and waist circumference are 
inexpensive and easy to perform assess-
ments that provide important clinical 
information in SLE and RA patients. 
Conversely, weight and BMI do not dis-
criminate between fat and fat-free body 
mass, which makes them less accurate 
measures for patients with chronic in-
ﬂammatory rheumatic diseases. 
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